The Zhitong Finance App learned that TreX Bio (TRXB.US), a biotech company focused on developing drugs for autoimmune and inflammatory diseases, announced its initial public offering (IPO) terms on Monday. The company plans to raise $125 million by issuing 8.3 million shares at a price of $14 to $16 each. LLY.US (LLY.US) plans to subscribe for $13 million worth of shares (10% of the total transaction) in this offering. Calculated at the midpoint of the issue price range, TreX Bio will reach a market value of US$453 million after complete dilution.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.